

CORRECTION

Open Access



Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer

Sunil Pancholi¹, Mariana Ferreira Leal¹, Ricardo Ribas¹, Nikiana Simigdala¹, Eugene Schuster¹, Sophie Chateau-Joubert², Lila Zabaglo¹, Margaret Hills³, Andrew Dodson³, Qiong Gao¹, Stephen R. Johnston⁴, Mitch Dowsett³, Sabina C. Cosulich⁵, Elisabetta Marangoni⁶ and Lesley-Ann Martin^{1*}

Correction to: *Breast Cancer Research* (2019) 21:135
<https://doi.org/10.1186/s13058-019-1222-0>

After publication of the original article [1], we were notified that an author's surname has been erroneously spelled. Elisabetta Maragoni's family name should be replaced with Marangoni.

Author details

¹Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW7 3RP, UK. ²BioPole Alfort, Ecole Nationale Veterinaire d'Alfort, Maisons Alfort, France. ³Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London SW3 6JJ, UK. ⁴Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK. ⁵Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK. ⁶Department of Translational Research, Institut Curie, Paris, France.

Published online: 31 January 2020

Reference

1. Pancholi S, et al. Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer. *Breast Cancer Res.* 2019;21:135. <https://doi.org/10.1186/s13058-019-1222-0>.

The original article can be found online at <https://doi.org/10.1186/s13058-019-1222-0>

* Correspondence: lesley-ann.martin@icr.ac.uk

¹Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW7 3RP, UK

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.